Description
BLOOD AND BLOOD PRODUCTS FOR VISN 12
First action · last action
2010-10-01 · 2011-10-01
Transactions
3
First transaction's obligation
$1,200,000
Base + all options value (sum of deltas)
$877,310
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
NO SET ASIDE USED.
Offers received
3
SDVOSB flag on record
No
Parent IDV
VA69DP1507
NAICS
621991 · BLOOD AND ORGAN BANKS
Modification chain · 3 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2010-10-01+$1,200,000= $1,200,000
- Mod 22011-09-30-$222,690= $977,310
- Mod 12011-10-01-$100,000= $877,310
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2010-10-01 | +$1,200,000 | $1,200,000 | BLOOD AND BLOOD PRODUCTS FOR VISN 12 |
| Mod 2· CLOSE OUT | 2011-09-30 | −$222,690 | $977,310 | BLOOD AND BLOOD PRODUCTS FOR VISN 12 |
| Mod 1· FUNDING ONLY ACTION | 2011-10-01 | −$100,000 | $877,310 | BLOOD AND BLOOD PRODUCTS FOR VISN 12 |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI JZDRNT166LE4)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C25226N0039 | 252-NETWORK CONTRACT OFFICE 12 (36C252) · 6505 · DRUGS AND BIOLOGICALS | $750,000 | FY2026 |
| 36C25226N0044 | 252-NETWORK CONTRACT OFFICE 12 (36C252) · 6505 · DRUGS AND BIOLOGICALS | $302,500 | FY2026 |
| 36C25226N0036 | 252-NETWORK CONTRACT OFFICE 12 (36C252) · 6505 · DRUGS AND BIOLOGICALS | $460,000 | FY2026 |
| 36C25226N0038 | 252-NETWORK CONTRACT OFFICE 12 (36C252) · 6505 · DRUGS AND BIOLOGICALS | $15,000 | FY2026 |
| 36C25226N0043 | 252-NETWORK CONTRACT OFFICE 12 (36C252) · 6505 · DRUGS AND BIOLOGICALS | $560,000 | FY2026 |
| 36C25226N0069 | 252-NETWORK CONTRACT OFFICE 12 (36C252) · 6505 · DRUGS AND BIOLOGICALS | $900,000 | FY2026 |
Other recipients under 6505 from 69D-NETWORK CONTRACT OFFICE 12 (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| VA69D16F2903 | CSL BEHRING L.L.C. | 69D-NETWORK CONTRACT OFFICE 12 | $5,443 | FY2016 |
| VA69D16F2824 | SANOFI VACCINES US INC. | 69D-NETWORK CONTRACT OFFICE 12 | $53,837 | FY2016 |
| VA69D16F2687 | SEQIRUS USA INC | 69D-NETWORK CONTRACT OFFICE 12 | $54,563 | FY2016 |
| VA69D16F2660 | SEQIRUS USA INC | 69D-NETWORK CONTRACT OFFICE 12 | $125,000 | FY2016 |
| VA69D16F2658 | SANOFI VACCINES US INC. | 69D-NETWORK CONTRACT OFFICE 12 | $141,675 | FY2016 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA69D695C10217_3600_VA69DP1507_3600 · retrieved 2026-09-26.